oxalobacter formigenes

Oxalobacter formigenes is a live biotherapeutic product being developed by OxThera under the brand name Oxabact®. It is an oral capsule containing a lyophilized (freeze-dried) formulation of the anaerobic bacterium *Oxalobacter formigenes*, which exclusively uses oxalate as its energy source. [3, 12, 16] The drug is intended for the treatment of Primary Hyperoxaluria (PH), a rare genetic disease characterized by the overproduction of oxalate, leading to kidney stones, nephrocalcinosis, and kidney failure. [2, 5] The mechanism of action is bimodal: the bacteria directly degrade oxalate within the gut, and they also produce secretagogues that stimulate the active secretion of oxalate from the bloodstream into the gut, further reducing the body's systemic oxalate burden. [7, 9, 14, 15] Clinical trials have evaluated its efficacy in reducing both plasma and urinary oxalate levels. [3, 11] While a Phase 3 study did not meet its primary endpoint with statistical significance, long-term extension studies have shown benefits. [13, 16]

Brand names

Oxabact

Other names

oxalobacter formigenes HC-1O. formigenes HC-1